Remdesivir in Very Old Patients (=80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.
Por:
Ramos-Rincon JM, López-Carmona MD, Cobos-Palacios L, López-Sampalo A, Rubio-Rivas M, Martín-Escalante MD, de-Cossio-Tejido S, Taboada-Martínez ML, Muiño-Miguez A, Areses-Manrique M, Martinez-Cilleros C, Tuñón-de-Almeida C, Abella-Vázquez L, Martínez-Gonzalez AL, Díez-García LF, Ripper CJ, Asensi V, Martinez-Pascual A, Guisado-Vasco P, Lumbreras-Bermejo C, Gómez-Huelgas R and On Behalf Of The Semi-Covid-Network
Publicada:
29 jun 2022
Ahead of Print:
29 jun 2022
Resumen:
(1) Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2) Methods: This is a retrospective analysis of patients = 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. (3) Results: Of the 4331 patients admitted, 1312 (30.3%) were =80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29-0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22-0.61) (p < 0.001)). (4) Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19.
Open Access
FULL TEXT
 |
Published Version |
|
| No Accesible |
|